110 results
8-K
EX-4.1
URGN
UroGen Pharma Ltd
18 Jun 24
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
5:07pm
for Ordinary Shares upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other … incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such or book entry shares, all of which taxes and expenses
8-K
EX-1.1
URGN
UroGen Pharma Ltd
18 Jun 24
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
5:07pm
the “capital gains track” or the “employment income track” of Section 102 of the Israeli Income Tax Ordinance (New Version), 5721-1961, and the rules … not apply to any intellectual property rights, which are covered by the representations and warranties contained in Section 1(t) hereof.
(w) Tax Law
424B5
URGN
UroGen Pharma Ltd
18 Jun 24
Prospectus supplement for primary offering
5:05pm
Tax Disclosure
S-24
Underwriting
S-35
Legal Matters
S-43
Experts
S-43
Where You Can Find More Information
S-43
Incorporation of Certain Information … securities, your ownership will be further diluted.
S-23
TAX DISCLOSURE
THE FOLLOWING DESCRIPTION IS NOT INTENDED TO CONSTITUTE A COMPLETE ANALYSIS
424B5
URGN
UroGen Pharma Ltd
17 Jun 24
Prospectus supplement for primary offering
4:19pm
of Proceeds
S-10
Description of Share Capital
S-11
Description of Securities We Are Offering
S-20
Dilution
S-22
Tax Disclosure
S-24
Underwriting
S … equity securities or convertible securities, your ownership will be further diluted.
S-23
TAX DISCLOSURE
THE FOLLOWING DESCRIPTION IS NOT INTENDED
8-K
EX-99.1
gj98vo1anm7kixlqf rt
13 May 24
ENVISION data expected to support completion of UGN-102 NDA in Q3 2024
8:01am
8-K
EX-99.1
y1qqxu70
14 Mar 24
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
8:16am
8-K
EX-99.1
zkgj6sh
14 Nov 23
UroGen Pharma Reports Third Quarter 2023 Financial Results
12:00am